Table 2.
In vitro Activities of Ceftazidime-Avibactam and Comparator Antimicrobial Agents Tested Against 43 CRKP Isolates (μg/mL)
| Antibiotics | MIC (μg/mL) | Antimicrobial Susceptibility | |||
|---|---|---|---|---|---|
| MIC Range | MIC50 | MIC90 | R (%) | S (%) | |
| CZA | ≤0.25/4->32/4 | 0.5 | >32 | 23.3 | 76.7 |
| CZT | ≤0.5/4->64/4 | >16 | >16 | 100.0 | 0.0 |
| TZP | ≤4/4->256/4 | >256/4 | >256/4 | 100.0 | 0.0 |
| CSL | ≤1/0.5->128/64 | >128 | >128 | 100.0 | 0.0 |
| PIP | ≤2->256 | >256 | >256 | 100.0 | 0.0 |
| CZO | ≤0.5->32 | >32 | >32 | 100.0 | 0.0 |
| CMZ | ≤0.5->64 | >64 | >64 | 100.0 | 0.0 |
| CXM | ≤1->64 | >64 | >64 | 100.0 | 0.0 |
| CAZ | ≤0.25->32 | >32 | >32 | 100.0 | 0.0 |
| CRO | ≤0.25->32 | >32 | >32 | 100.0 | 0.0 |
| FEP | ≤16->32 | >32 | >32 | 100.0 | 0.0 |
| IPM | ≤0.12->16 | >16 | >16 | 100.0 | 0.0 |
| MEM | ≤0.12->16 | >16 | >16 | 100.0 | 0.0 |
| ETP | ≤0.25->32 | >32 | >32 | 100.0 | 0.0 |
| AMK | ≤1->128 | >128 | >128 | 74.4 | 25.6 |
| GEN | ≤1->128 | >128 | >128 | 97.7 | 0.0 |
| NIT | ≤2->128 | >128 | >128 | 88.4 | 2.3 |
| SXT | ≤0.25/4.75->32/608 | 0.25/4.75 | 32/608 | 25.5 | 74.4 |
| ATM | ≤1->128 | >128 | >128 | 95.3 | 0.0 |
| LVX | ≤0.12->16 | >16 | >16 | 86.0 | 14.0 |
| CIP | ≤0.06->8 | >8 | >8 | 86.0 | 14.0 |
| DOX | ≤1->128 | 4.0 | 32.0 | 44.2 | 55.8 |
| POL | ≤0.25->16 | 0.5 | 1.0 | 0.0 | 100.0 |
| TGC | ≤0.12->16 | 1.0 | 1.0 | 0.0 | 100.0 |
Abbreviations: CZA, ceftazidime/avibactam; CZT, ceftolozane/tazobactam; TZP, piperacillin-tazobactam; CSL, cefoperazone/sulbactam; PIP, piperacillin; CZO, cefazolin; CMZ, cefmetazole; CXM, cefuroxime; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; IMP, imipenem; MEM, meropenem; ETP, ertapenem; AMK, amikacin; GEN, gentamicin; NIT, nitrofurantoin; SXT, trimethoprim/sulfamethoxazole; ATM, aztreonam; LVX, levofloxacin; CIP, ciprofloxacin; DOX, doxycycline; POL, polymyxin B; TGC, tigecycline.